Spots Global Cancer Trial Database for mds
Every month we try and update this database with for mds cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome | NCT01513317 | Myelodysplastic... | Siltuximab Placebo Best supportive... | 18 Years - | Janssen Research & Development, LLC | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) | NCT02243124 | Myelodysplastic... | cenersen Dexamethasone | 18 Years - 95 Years | Eleos, Inc. | |
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment | NCT02099266 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Hodgkins Lympho... Non-Hodgkins Ly... | Administration ... | 17 Years - 70 Years | University of Kansas Medical Center | |
| Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome | NCT01053806 | Myelodysplastic... | 5-Azacytidine a... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA | NCT02562443 | Myelodysplastic... MDS Refractory Anem... RAEB | rigosertib Any approved or... best supportive... best supportive... | 18 Years - 81 Years | Traws Pharma, Inc. | |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | NCT04217278 | Acute Myeloid L... High-risk Myelo... | Vyxeos Fludarabine Busulphan Thiotepa Cytarabine | 18 Years - | University of Birmingham | |
| Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome | NCT01311258 | Acute Myeloid L... Myelodysplastic... | 18 Years - | University of Rochester | ||
| Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | NCT00720850 | Myelodysplastic... Acute Myelogeno... | lenalidomide | 18 Years - | Technische Universität Dresden | |
| Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT05961839 | Acute Myeloid L... High-Risk and V... | SGR-2921 | 18 Years - | Schrödinger, Inc. | |
| Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | NCT02272478 | Acute Myeloid L... Myelodysplastic... | Arm A Mylotarg ... Arm B Vosaroxin... Arm D Small mol... Arm C DA V FLAG... Arm E CPX-351 (... Arm F DA V IDAC | 60 Years - | Cardiff University | |
| A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) | NCT05568225 | Very Low Risk, ... | Etavopivat | 18 Years - | Novo Nordisk A/S | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | NCT00357565 | Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo... | filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ... | - 3 Years | Masonic Cancer Center, University of Minnesota | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | NCT03417154 | Acute Myeloid L... Higher Risk Mye... | Nivolumab Low dose Cyclop... Low dose Cyclop... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00948064 | Leukemia | Vorinostat Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes | NCT03446638 | Myelodysplastic... | FDA-approved dr... FLAG induction 7 + 3 induction Low-dose cytara... Supportive care... Computational b... | 18 Years - 99 Years | University of Florida | |
| SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | NCT01261312 | MDS CMML AML | SGI-110 SGI-110 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT00778375 | Acute Myeloid L... Myelodysplastic... | Clofarabine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | NCT00038805 | Leukemia | Mylotarg | 55 Years - 75 Years | M.D. Anderson Cancer Center | |
| Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging | NCT02193581 | Skin Lesion | MDS | 21 Years - | Orlucent, Inc | |
| A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00136461 | Acute Myelogeno... Myelodysplastic... | All-trans retin... Bryostatin 1 | 18 Years - | Dana-Farber Cancer Institute | |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | NCT00689000 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CHR-2797 (tosed... | 18 Years - | Chroma Therapeutics | |
| Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through Demethylation | NCT05687513 | MDS | Yisui granule Placebo | 18 Years - 85 Years | Dongzhimen Hospital, Beijing | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| Biology Studies of Hematologic Cancers | NCT00923442 | Acute Lymphobla... Myelodysplastic... Non-Hodgkins Ly... Acute Myelogeno... Hodgkins Lympho... | 1 Year - 75 Years | National Institutes of Health Clinical Center (CC) | ||
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure. | NCT04109690 | MDS | CPX-351 | 18 Years - 78 Years | Yale University | |
| Shwachman Diamond Syndrome Registry and Study | NCT06056908 | Shwachman-Diamo... Shwachman-Diamo... | - | Boston Children's Hospital | ||
| Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01362140 | MDS | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome | NCT01584531 | Myelodysplastic... MDS Trisomy 8 | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study | NCT00715637 | Secondary Acute... | Daunorubicin an... Amonafide and C... | 18 Years - | Antisoma Research | |
| A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. | NCT02663752 | Myelodysplastic... | Bone marrow asp... Deferasirox | 18 Years - | Novartis | |
| Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes | NCT00064974 | Myelodysplastic... | CC-5013 | 18 Years - | Celgene | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes | NCT03151304 | Myelodysplastic... | Pracinostat Azacitidine | 18 Years - | Helsinn Healthcare SA | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | NCT02631070 | Myelodysplastic... | Luspatercept Placebo | 18 Years - | Celgene | |
| Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias | NCT00920140 | Cancer | GSK1120212 GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Allogeneic Transplant in HIV Patients (BMT CTN 0903) | NCT01410344 | Leukemia Lymphoma HIV | Fludarabine and... Fludarabine and... Busulfan and Fl... Cyclophosphamid... | 15 Years - | Medical College of Wisconsin | |
| PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | NCT03927261 | Acute Myeloid L... Myelodysplastic... | PRGN-3006 T Cel... | 18 Years - | Precigen, Inc | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients | NCT00446303 | Leukemia, Myelo... Myelodysplastic... | Azacitidine | 18 Years - 85 Years | Groupe Francophone des Myelodysplasies | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | NCT02492737 | Acute Myeloid L... Myelodysplastic... Hematologic Mal... | AG881 | 18 Years - | Agios Pharmaceuticals, Inc. | |
| Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia | NCT00671697 | Myelodysplastic... | Arsenic Trioxid... Decitabine | 18 Years - | Washington University School of Medicine | |
| Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS) | NCT00840931 | Leukemia | lenalidomide bystander vacci... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes | NCT01342692 | MDS | Azacitidine Azacitidine ass... Azacitidine ass... Azacitidine ass... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | NCT02018926 | Myelodysplastic... | Mocetinostat Azacitidine | 18 Years - | Mirati Therapeutics Inc. | |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | NCT00506857 | Hematologic Mal... | Busulfan Fludarabine | - 75 Years | M.D. Anderson Cancer Center | |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | NCT02743351 | Hematologic Mal... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Acute Graft-ver... | ProTmune Control Arm | 18 Years - | Fate Therapeutics | |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | NCT02018926 | Myelodysplastic... | Mocetinostat Azacitidine | 18 Years - | Mirati Therapeutics Inc. | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| National Longitudinal Cohort of Hematological Diseases | NCT04645199 | Multiple Myelom... Myeloma, Multip... Myelomas, Multi... Acute Myeloid L... Leukemias, Acut... Myeloid Leukemi... Hemophilia Hemophilia A Hemophilia As Hemophilia B Hemophilia Bs Myelodysplastic... MDS Lymphoma Leukemia Aplastic Anemia Bleeding Disord... Bone Marrow Tra... Blood Disease I... | - | Institute of Hematology & Blood Diseases Hospital, China | ||
| A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | NCT02732184 | Acute Myeloid L... Myelodysplastic... | Co-ArgI-PEG mod... | 18 Years - 90 Years | Aeglea Biotherapeutics | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA | NCT04798339 | Myelodysplastic... | Canakinumab Inj... Darbepoetin Alf... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | NCT01404741 | Myelodysplastic... Chronic Myelomo... | allogeneic stem... 5-azacytidine u... | 55 Years - 70 Years | Universitätsklinikum Hamburg-Eppendorf | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS) | NCT00120653 | Myelodysplastic... | Metoclopramide | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | NCT03493646 | Myelodysplastic... Acute Myeloid L... Chronic Myelomo... | Azacitidine CC-486 | 18 Years - | Kirby Institute | |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01019317 | Leukemia AML MDS CML | Cytarabine Fludarabine | 12 Years - | M.D. Anderson Cancer Center | |
| Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) | NCT02279654 | Myelodysplastic... | Lenalidomide | 18 Years - | Celgene | |
| PR1 Vaccination in Myelodysplastic Syndrome (MDS) | NCT00893997 | Leukemia Myelodysplastic... | PR-1 vaccine | 18 Years - | M.D. Anderson Cancer Center | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | NCT05170828 | Acute Leukemia Myelodysplastic... T-lymphoblastic... Acute Lymphocyt... Acute Myeloid L... Acute Biphenoty... Acute Undiffere... | Cyclophosphamid... Fludarabine Total Body Irra... Busulfan Mesna Sirolimus Mycophenolate M... Filgrastim Cyclophosphamid... Bone Marrow Tra... | 18 Years - 70 Years | Ossium Health, Inc. | |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | NCT04395092 | Acute Myeloid L... Myelodysplastic... | K-NK002 Conditioning Re... HaploBMT | 18 Years - 65 Years | Kiadis Pharma | |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies | NCT01204164 | AML ALL Blast Crisis MDS Multiple Myelom... | TG02 citrate Carfilzomib Dexamethasone | 18 Years - | Tragara Pharmaceuticals, Inc. | |
| Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS | NCT01133275 | Myelodysplastic... MDS | Prednisone Lenalidomide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | NCT00469144 | Myelodysplastic... Leukemia Acute Myeloid L... | Busulfan Fludarabine | - 65 Years | M.D. Anderson Cancer Center | |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | NCT05476770 | Hematologic Mal... AML ALL BPDCN MDS Lymphoblastic L... Lymphoma, B-Cel... Lymphoma, T-Cel... Hodgkin Lymphom... Mixed Phenotype... Acute Undiffere... | Tagraxofusp Fludarabine Cytarabine Dexamethasone Vincristine Azacitidine Methotrexate Cytarabine IT Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
